MX378108B - Anticuerpos anti-met y composiciones. - Google Patents

Anticuerpos anti-met y composiciones.

Info

Publication number
MX378108B
MX378108B MX2017003211A MX2017003211A MX378108B MX 378108 B MX378108 B MX 378108B MX 2017003211 A MX2017003211 A MX 2017003211A MX 2017003211 A MX2017003211 A MX 2017003211A MX 378108 B MX378108 B MX 378108B
Authority
MX
Mexico
Prior art keywords
compositions
met
antibodies
met antibodies
cancer
Prior art date
Application number
MX2017003211A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003211A (es
Inventor
Helle Jane Jacobsen
Karsten Wessel Eriksen
Klaus Koefoed
Michael Kragh
Michael Monrad Grandal
Mikkel Wandahl Pedersen
Paolo Conrotto
Thomas Bouquin
Thomas Tuxen Poulsen
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2017003211A publication Critical patent/MX2017003211A/es
Publication of MX378108B publication Critical patent/MX378108B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017003211A 2014-09-16 2015-09-15 Anticuerpos anti-met y composiciones. MX378108B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051190P 2014-09-16 2014-09-16
PCT/IB2015/002110 WO2016042412A1 (en) 2014-09-16 2015-09-15 Anti-met antibodies and compositions

Publications (2)

Publication Number Publication Date
MX2017003211A MX2017003211A (es) 2017-06-06
MX378108B true MX378108B (es) 2025-03-10

Family

ID=54780359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003211A MX378108B (es) 2014-09-16 2015-09-15 Anticuerpos anti-met y composiciones.

Country Status (11)

Country Link
US (1) US10450376B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194444B1 (cg-RX-API-DMAC7.html)
JP (1) JP6927875B2 (cg-RX-API-DMAC7.html)
KR (1) KR102200274B1 (cg-RX-API-DMAC7.html)
CN (1) CN107001471B (cg-RX-API-DMAC7.html)
AU (1) AU2015316522B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961323C (cg-RX-API-DMAC7.html)
ES (1) ES2748295T3 (cg-RX-API-DMAC7.html)
IL (1) IL250902B (cg-RX-API-DMAC7.html)
MX (1) MX378108B (cg-RX-API-DMAC7.html)
WO (1) WO2016042412A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2864150T3 (es) 2016-05-17 2021-10-13 Abbvie Biotherapeutics Inc Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
CA3036643C (en) 2016-09-29 2021-10-26 Mitsubishi Tanabe Pharma Corporation Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
KR20200012937A (ko) 2017-06-06 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도
SG11202009308WA (en) * 2018-03-28 2020-10-29 Mitsubishi Tanabe Pharma Corp DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF
KR102221755B1 (ko) * 2018-05-02 2021-03-02 (주)에임드바이오 c-Met에 특이적으로 결합하는 항체 및 그의 용도
KR102433184B1 (ko) * 2018-12-07 2022-08-17 서울대학교 산학협력단 항 c-Met 아고니스트 항체 및 이의 용도
AU2020308053A1 (en) * 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
US11896682B2 (en) 2019-09-16 2024-02-13 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
WO2021058735A1 (en) 2019-09-26 2021-04-01 Symphogen A/S Cancer treatment with anti-met antibody compositions
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment
AU2022254291A1 (en) 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
EP4472997A2 (en) * 2022-02-02 2024-12-11 The Broad Institute, Inc. Targeting moieties promoting transduction of central nervous system cells and tissues and methods of use
JP2025517429A (ja) 2022-05-20 2025-06-05 ノバルティス アーゲー Ｍｅｔ ｂｃｌ－ｘｌ阻害剤抗体－薬物コンジュゲートおよびその使用の方法
TW202500584A (zh) 2023-05-19 2025-01-01 法商施維雅藥廠 抗met抗體、抗體-藥物結合物、組合物及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
CA2144856A1 (en) 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
US20090068179A1 (en) 2005-11-16 2009-03-12 Fariba Nayeri Methods for Inhibiting Carcinogenesis and/or Metastasis in an Individual with Endogenous C-Met Ligands and Inhibitors
BRPI0707480A8 (pt) 2006-02-06 2022-11-08 Vertical Bio Ag Usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotídeos e de um vetor, produto, e, método para triar compostos
CA2646620C (en) 2006-03-20 2015-07-14 Seikagaku Corporation Therapeutic agent for rheumatoid arthritis
JP5536445B2 (ja) 2006-03-30 2014-07-02 ノバルティス アーゲー ｃ−Ｍｅｔの抗体の組成物およびその使用方法
US8039598B2 (en) 2007-01-19 2011-10-18 Van Andel Research Institute Met fab and SCFV fragments
EP2152872B1 (en) 2007-05-25 2010-09-15 Symphogen A/S Method for manufacturing a recombinant polyclonal protein
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
WO2009129814A1 (en) 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
WO2009142738A2 (en) * 2008-05-21 2009-11-26 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP4083072A1 (en) * 2008-10-06 2022-11-02 Minerva Biotechnologies Corporation Muc1* antibodies
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
JP6055312B2 (ja) 2010-03-10 2017-01-11 ゲンマブ エー／エス Ｃ−ｍｅｔに対するモノクローナル抗体
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
US8637027B2 (en) 2010-11-03 2014-01-28 Argen-X B.V. Anti c-Met antibodies

Also Published As

Publication number Publication date
IL250902A0 (en) 2017-04-30
WO2016042412A1 (en) 2016-03-24
EP3194444B1 (en) 2019-07-10
US10450376B2 (en) 2019-10-22
JP2017534259A (ja) 2017-11-24
IL250902B (en) 2022-08-01
CA2961323A1 (en) 2016-03-24
AU2015316522A1 (en) 2017-03-23
KR102200274B1 (ko) 2021-01-08
AU2015316522B2 (en) 2021-01-21
JP6927875B2 (ja) 2021-09-01
CN107001471A (zh) 2017-08-01
CA2961323C (en) 2021-11-30
CN107001471B (zh) 2022-01-18
KR20170054517A (ko) 2017-05-17
BR112017005202A2 (pt) 2017-12-12
EP3194444A1 (en) 2017-07-26
ES2748295T3 (es) 2020-03-16
US20180327500A1 (en) 2018-11-15
MX2017003211A (es) 2017-06-06

Similar Documents

Publication Publication Date Title
MX378108B (es) Anticuerpos anti-met y composiciones.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
NI201700019A (es) Anticuerpos anti tigit
ECSP19020740A (es) Anticuerpos anti-cd27
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
AR091837A1 (es) Compuestos para inmunoterapia dirigida
MX391159B (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
DOP2017000298A (es) Reguladores de nrf2
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
MX385842B (es) Conjugados de partículas de tipo virus y uso de las mismas.
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2013012896A (es) Compuestos novedosos como moduladores de proteina cinasas.
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX373333B (es) Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina y métodos de uso.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX2017009608A (es) Compuestos anticancerigenos.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.